$1.00
-0.02 (-1.96%)
Open$1.01
Previous Close$1.02
Day High$1.01
Day Low$0.98
52W High$3.68
52W Low$0.68
Volume—
Avg Volume18.5K
Market Cap12.07M
P/E Ratio—
EPS$-0.34
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,331.0% upside
Current
$1.00
$1.00
Target
$24.31
$24.31
$15.00
$24.31 avg
$29.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 330.1K | 1.99M | 1.82M |
| Net Income | -4,044,463 | -271,887 | -219,394 |
| Profit Margin | -1,227.1% | -13.7% | -12.0% |
| EBITDA | -3,651,612 | -443,981 | -374,843 |
| Free Cash Flow | — | -242,138 | -341,295 |
| Rev Growth | — | +6.4% | +1.5% |
| Debt/Equity | 0.07 | 0.27 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |